A number of MCHR1 antagonists have been developed as potential anti-obesity drugs (Borowsky et al. 2002; Luthin 2007; Gehlert et al. 2009; Jeon and Cheon 2009). Here, MCHR1 is linked to obesity due to melanocortin 4 receptor deficiency.